163 related articles for article (PubMed ID: 32485328)
1. Randomized trial of argatroban plus recombinant tissue-type plasminogen activator for acute ischemic stroke (ARAIS): Rationale and design.
Yang Y; Zhou Z; Pan Y; Chen H; Wang Y;
Am Heart J; 2020 Jul; 225():38-43. PubMed ID: 32485328
[TBL] [Abstract][Full Text] [Related]
2. The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study.
Barreto AD; Alexandrov AV; Lyden P; Lee J; Martin-Schild S; Shen L; Wu TC; Sisson A; Pandurengan R; Chen Z; Rahbar MH; Balucani C; Barlinn K; Sugg RM; Garami Z; Tsivgoulis G; Gonzales NR; Savitz SI; Mikulik R; Demchuk AM; Grotta JC
Stroke; 2012 Mar; 43(3):770-5. PubMed ID: 22223235
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).
Barreto AD; Ford GA; Shen L; Pedroza C; Tyson J; Cai C; Rahbar MH; Grotta JC;
Stroke; 2017 Jun; 48(6):1608-1616. PubMed ID: 28507269
[TBL] [Abstract][Full Text] [Related]
4. Effect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke: The ARAIS Randomized Clinical Trial.
Chen HS; Cui Y; Zhou ZH; Dai YJ; Li GH; Peng ZL; Zhang Y; Liu XD; Yuan ZM; Jiang CH; Yang QC; Duan YJ; Ma GB; Zhao LW; Wang RX; Sun YL; Shen L; Wang EQ; Wang LH; Feng YF; Wang FY; Zou RL; Yang HP; Wang K; Wang DL; Wang YL;
JAMA; 2023 Feb; 329(8):640-650. PubMed ID: 36757755
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of argatroban in the management of acute ischemic stroke: A systematic literature review and meta-analysis.
Al-Salihi MM; Saha R; Ayyad A; Al-Jebur MS; Al-Salihi Y; Roy A; Dalal SS; Rivet D; Spiotta AM; Qureshi AI
Clin Neurol Neurosurg; 2024 Jan; 236():108097. PubMed ID: 38176219
[TBL] [Abstract][Full Text] [Related]
6. Safety and Feasibility of Argatroban, Recombinant Tissue Plasminogen Activator, and Intra-Arterial Therapy in Stroke (ARTSS-IA Study).
Berekashvili K; Soomro J; Shen L; Misra V; Chen PR; Blackburn S; Dannenbaum M; Grotta JC; Barreto AD
J Stroke Cerebrovasc Dis; 2018 Dec; 27(12):3647-3651. PubMed ID: 30249518
[TBL] [Abstract][Full Text] [Related]
7. Argatroban in Patients With Acute Ischemic Stroke With Early Neurological Deterioration: A Randomized Clinical Trial.
Zhang X; Zhong W; Xue R; Jin H; Gong X; Huang Y; Chen F; Chen M; Gu L; Ge Y; Ma X; Zhong B; Wang M; Hu H; Chen Z; Yan S; Chen Y; Wang X; Zhang X; Xu D; He Y; Lou M; Wang A; Zhang X; Ma L; Lu X; Wang J; Lou Q; Qian P; Xie G; Zhu X; He S; Hu J; Wen X; Liu Y; Wang Y; Fu J; Fan W; Liebeskind D; Yuan C; Lou M
JAMA Neurol; 2024 Feb; 81(2):118-125. PubMed ID: 38190136
[TBL] [Abstract][Full Text] [Related]
8. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.
Adeoye O; Sucharew H; Khoury J; Tomsick T; Khatri P; Palesch Y; Schmit PA; Pancioli AM; Broderick JP;
Stroke; 2015 Feb; 46(2):461-4. PubMed ID: 25523054
[TBL] [Abstract][Full Text] [Related]
9. Argatroban tPA stroke study: study design and results in the first treated cohort.
Sugg RM; Pary JK; Uchino K; Baraniuk S; Shaltoni HM; Gonzales NR; Mikulik R; Garami Z; Shaw SG; Matherne DE; Moyé LA; Alexandrov AV; Grotta JC
Arch Neurol; 2006 Aug; 63(8):1057-62. PubMed ID: 16908730
[TBL] [Abstract][Full Text] [Related]
10. The multiarm optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: Rationale and methods.
Deeds SI; Barreto A; Elm J; Derdeyn CP; Berry S; Khatri P; Moy C; Janis S; Broderick J; Grotta J; Adeoye O
Int J Stroke; 2021 Oct; 16(7):873-880. PubMed ID: 33297893
[TBL] [Abstract][Full Text] [Related]
11. Argatroban Increased the Basal Vein Drainage and Improved Outcomes in Acute Paraventricular Ischemic Stroke Patients.
Liu S; Liu P; Wang P; Zhang F; Wang L; Wang Y; Lu H; Ma X
Med Sci Monit; 2020 Jul; 26():e924593. PubMed ID: 32667287
[TBL] [Abstract][Full Text] [Related]
12. Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial.
Adeoye O; Sucharew H; Khoury J; Vagal A; Schmit PA; Ewing I; Levine SR; Demel S; Eckerle B; Katz B; Kleindorfer D; Stettler B; Woo D; Khatri P; Broderick JP; Pancioli AM
Stroke; 2015 Sep; 46(9):2529-33. PubMed ID: 26243231
[TBL] [Abstract][Full Text] [Related]
13. Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke.
Saver JL; Goyal M; Bonafe A; Diener HC; Levy EI; Pereira VM; Albers GW; Cognard C; Cohen DJ; Hacke W; Jansen O; Jovin TG; Mattle HP; Nogueira RG; Siddiqui AH; Yavagal DR; Devlin TG; Lopes DK; Reddy V; du Mesnil de Rochemont R; Jahan R;
Int J Stroke; 2015 Apr; 10(3):439-48. PubMed ID: 25777831
[TBL] [Abstract][Full Text] [Related]
14. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.
Pancioli AM; Broderick J; Brott T; Tomsick T; Khoury J; Bean J; del Zoppo G; Kleindorfer D; Woo D; Khatri P; Castaldo J; Frey J; Gebel J; Kasner S; Kidwell C; Kwiatkowski T; Libman R; Mackenzie R; Scott P; Starkman S; Thurman RJ;
Stroke; 2008 Dec; 39(12):3268-76. PubMed ID: 18772447
[TBL] [Abstract][Full Text] [Related]
15. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study.
LaMonte MP; Nash ML; Wang DZ; Woolfenden AR; Schultz J; Hursting MJ; Brown PM;
Stroke; 2004 Jul; 35(7):1677-82. PubMed ID: 15155959
[TBL] [Abstract][Full Text] [Related]
16. CLOTBUST: design of a randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke.
Alexandrov AV; Wojner AW; Grotta JC;
J Neuroimaging; 2004 Apr; 14(2):108-12. PubMed ID: 15095554
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials.
Ramakrishnan TCR; Kumaravelu S; Narayan SK; Buddha SS; Murali C; Majeed PHA; Meenakshi-Sundaram S; Wadia RS; Sharma V; Basu I; Vijaya P; Salam KA; Barmare S; Vaid Z; Nirmal Raj KK; Wattamwar PR; Asokan K; Dhonge V; Nellikunja S; Namjoshi D; Srinivasa R; Laddhad DS; Deshpande SD; Raghunath B; Kalita J; Kumar M; Misra UK; Pradeep M;
Am J Cardiovasc Drugs; 2018 Oct; 18(5):387-395. PubMed ID: 29948822
[TBL] [Abstract][Full Text] [Related]
18. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke.
Morris DC; Zhang L; Zhang ZG; Lu M; Berens KL; Brown PM; Chopp M
Stroke; 2001 Nov; 32(11):2635-40. PubMed ID: 11692028
[TBL] [Abstract][Full Text] [Related]
19. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.
Albers GW; Bates VE; Clark WM; Bell R; Verro P; Hamilton SA
JAMA; 2000 Mar; 283(9):1145-50. PubMed ID: 10703776
[TBL] [Abstract][Full Text] [Related]
20. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
Ong CT; Wong YS; Wu CS; Su YH
Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
